Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 10/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | GLP1R | P43220 | 2/20 | 0.47 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1349261 | 1.00 | NOD1 (0.64) | NOD1KMT2ASLC6A5POLBCYP3A4 | |
| SCHEMBL9762122 | 1.00 | NOD1 (0.64) | NOD1KMT2ASLC6A5POLBCYP3A4 | |
| SCHEMBL29201432 | 0.94 | NOD1 (0.60) | NOD1KMT2ASLC6A5CYP3A4TSHR | |
| SCHEMBL28517679 | 0.93 | NOD1 (0.59) | NOD1KMT2ASLC6A5CYP3A4TSHR | |
| SCHEMBL3773050 | 0.93 | CYP3A4 (0.62) | NOD1KMT2ASLC6A5POLBCYP3A4 | |
| SCHEMBL155009 | 0.91 | KMT2A (0.64) | NOD1KMT2APOLBCYP3A4TSHR | |
| SCHEMBL9762126 | 0.91 | KMT2A (0.64) | NOD1KMT2APOLBCYP3A4TSHR | |
| SCHEMBL9762120 | 0.91 | KMT2A (0.64) | NOD1KMT2APOLBCYP3A4TSHR | |
| SCHEMBL29129967 | 0.91 | KMT2A (0.64) | NOD1KMT2APOLBCYP3A4TSHR | |
| SCHEMBL155007 | 0.91 | KMT2A (0.64) | NOD1KMT2APOLBCYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 718 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3449904-B1 | EMULSIFIED COSMETIC | SHINETSU CHEMICAL CO (JP) | 2024-06-19 | — | — | EP | claimed |
| US-20120321576-A1 | SUNSCREEN COMPOSITION | SHISEIDO COMPANY, LTD. (JP) | 2012-12-20 | — | — | US | claimed |
| EP-1466586-B1 | Water-in-oil emulsion preparation for external use on skin | NISSHIN OILLIO GROUP LTD (JP) | 2011-10-12 | — | — | EP | claimed |
| EP-1145707-A1 | COMPOSITIONS FOR EXTERNAL USE | SHISEIDO COMPANY LIMITED (JP) | 2001-10-17 | — | — | EP | claimed |
| US-20260144736-A1 | Aqueous Polymer Emulsion for Cosmetic, Method for Producing Same, and Cosmetic | TOAGOSEI CO., LTD. (JP) | 2026-05-28 | — | — | US | disclosed |
| US-12600821-B2 | Crosslinked organosilicon resin, a method for producing same, and a cosmetic | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2026-04-14 | — | — | US | disclosed |
| US-20260098007-A1 | Compounds and Their Use in Filtering Ultraviolet and/or High-Energy Visible Light | SOLIOME INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-12589062-B2 | Powdery solid cosmetic preparation | SHISEIDO COMPANY, LTD. (JP) | 2026-03-31 | — | — | US | disclosed |
| US-12569428-B2 | Oil-in-water cleansing cosmetic composition | DOW TORAY CO., LTD. (JP) | 2026-03-10 | — | — | US | disclosed |
| EP-3822303-B1 | CROSSLINKED ORGANOSILICON RESIN, METHOD FOR PRODUCING SAME, AND COSMETIC | SHINETSU CHEMICAL CO (JP) | 2026-03-04 | — | — | EP | disclosed |
| EP-3954357-B1 | OIL-IN-WATER-TYPE CLEANSING COSMETIC | DOW TORAY CO LTD (JP) | 2025-10-29 | — | — | EP | disclosed |
| US-12453694-B2 | Cosmetic composition | DOW TORAY CO., LTD. (JP) | 2025-10-28 | — | — | US | disclosed |
| EP-0795318-A2 | A w/o cosmetic emulsion containing ethylcellulose | SHISEIDO COMPANY LIMITED (JP) | 1997-09-17 | — | — | EP | disclosed |
| EP-0728469-A2 | An endermic liniment | SHISEIDO COMPANY LIMITED (JP) | 1996-08-28 | — | — | EP | disclosed |
| EP-0688559-A1 | Skin anti-ageing composition | SHISEIDO COMPANY LIMITED (JP) | 1995-12-27 | — | — | EP | disclosed |
| EP-0487404-B1 | External dermatological composition | HAYASHIBARA BIOCHEM LAB (JP) | 1995-10-11 | — | — | EP | disclosed |
| EP-0349150-B1 | Transparent compostition | SHISEIDO CO LTD (JP) | 1994-08-17 | — | — | EP | disclosed |
| US-5162377-A | Cosmetics, Drugs | SHISEIDO COMPANY, LTD. (JP) | 1992-11-10 | — | — | US | disclosed |
| EP-0487404-A1 | External dermatological composition | KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) | 1992-05-27 | — | — | EP | disclosed |
| EP-0349150-A2 | Transparent compostition | SHISEIDO COMPANY LIMITED (JP) | 1990-01-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600821-B2 | Crosslinked organosilicon resin, a method for producing same, and a cosmetic | DEGS1, HACL2, GAR1 | NOD1 3885/4885KMT2A 2394/4885SLC6A5 1759/4885 |
| US-12589062-B2 | Powdery solid cosmetic preparation | TMEM63A, CUTA, VCL | NOD1 4756/4885KMT2A 2005/4885SLC6A5 2550/4885 |
| US-12569428-B2 | Oil-in-water cleansing cosmetic composition | SGMS2, SGMS1, CUTA | NOD1 4535/4885KMT2A 2852/4885SLC6A5 1074/4885 |
| US-12453694-B2 | Cosmetic composition | CUTA, SLC30A7, SLC39A7 | NOD1 4718/4885KMT2A 904/4885SLC6A5 3323/4885 |
| US-20260098007-A1 | Compounds and Their Use in Filtering Ultraviolet and/or High-Energy Visible Light | UGT8, UGT1A3, FUT5 | NOD1 3329/4885KMT2A 1842/4885SLC6A5 1176/4885 |
| US-20260144736-A1 | Aqueous Polymer Emulsion for Cosmetic, Method for Producing Same, and Cosmetic | MMAB, RARB, RXRB | NOD1 4223/4885KMT2A 1273/4885SLC6A5 4268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.